The Latest Cardiac and Vascular News
LEIPZIG, Germany and MARLBOROUGH, Mass., Jan. 22, 2019 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive 12-month data demonstrating that patients who were treated with the VICI VENOUS STENT® System for iliac and femoral vein obstructions exhibited a high rate of patent, or open, target […]
MARLBOROUGH, Mass. and IRVINE, Calif., Jan. 15, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) and Edwards Lifesciences Corporation (NYSE: EW) today announced that the companies have reached an agreement to settle all outstanding patent disputes between the companies in all venues around the world. All […]
MARLBOROUGH, Mass., Jan. 8, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.56 billion during the fourth quarter of 2018. This represents growth of approximately 6.3 percent on a reported basis, approximately 8.2 […]
MARLBOROUGH, Mass., Dec. 27, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Millipede, Inc, a privately-held company in Santa Rosa, Calif., upon its recent successful completion of a first-in-human clinical study. The acquisition […]
MARLBOROUGH, Mass., Dec. 11, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that a jury in the United States (U.S.) District Court for the District of Delaware determined that the Boston Scientific U.S. patent 8,992,608 is valid and that Edwards Lifesciences’ Sapien 3™ Aortic Valve infringes […]
IRVINE, Calif., Dec. 11, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, commented today on a federal jury’s decisions in patent litigation between Edwards and Boston Scientific: The jury […]
MARLBOROUGH, Mass., Nov. 20, 2018 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a company headquartered in the United Kingdom, which develops and commercializes products used […]
MARLBOROUGH, Mass., Oct. 23, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the District Court of Dusseldorf, Germany has determined that Edwards Lifesciences Corporation’s Sapien 3 Ultra™ device infringed a patent – established by Symetis SA, a subsidiary of […]
MARLBOROUGH, Mass., Sept. 24, 2018 /PRNewswire/ — Today, Boston Scientific (NYSE :BSX ) announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application to market the Eluvia™Drug-Eluting Vascular Stent System, specifically developed for the treatment of peripheral artery disease […]
MARLBOROUGH, Mass., Sept. 17, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE :BSX ) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in San Diego, on September 21 – September […]
